no results
Ihre Produkte genau hier!
Ihre Suche lieferte keine Ergebnisse, aber Sie können sich mit Ihren Produkten und Leistungen auf dieser Seite präsentieren
Mit einem Eintrag auf Weltzentrum der Medizintechnik platzieren Sie Ihre Produkte und Dienstleistungen bei Google & Co. ganz weit oben und erreichen so jeden Tag mehrere Tausend potentielle Kunden aus der Medizintechnikbranche. Mehr Informationen gibt es auf der Firma eintragen - Seite.
no results
Ihr Unternehmen genau hier!
Ihre Suche lieferte keine Ergebnisse, aber Sie können sich auf dieser Seite präsentieren
Mit einem Eintrag auf Weltzentrum der Medizintechnik platzieren Sie Ihr Unternehmen bei Google & Co. ganz weit oben und erreichen so jeden Tag mehrere Tausend potentielle Kunden aus der Medizintechnikbranche. Mehr Informationen gibt es auf der Firma eintragen - Seite.
Arterial, vein and vascular prostheses
Aortic injuries are commonly treated surgically with resection of the damaged segment and reconstruction with a synthetic graft. The great saphenous vein is a superior autologous graft to vena cava conduits. Although the aortic conduit is not a growth factor, it is the most reliable option for children who do not require aortic valve replacement.
Various types of vascular prostheses have been developed over the years. A stent-graft is one of the most common and promising options. This device was first implanted into dogs in 1972. Later, it was modified to encourage tissue ingrowth and viable neointima. This medical device has been used to treat pancreatic and biliary artery cancers.
Arterial vein and vascular prosthesed have been used in the treatment of aortic aneurysms for decades. Despite their success, many limitations still remain. The risks of this procedure are high, especially for patients with large aneurysms. There are several complications that can arise from a vascular prosthesis, including bleeding and infection. The complications that can occur during surgery may also be serious.
There are a number of limitations to vascular prostheses. The greatest limitations of this device are the risks of thrombogenicity and the fact that the conduit is not grown with the child's aorta. There are many alternatives to the stent, but no one therapy is effective for all patients. And while there are a variety of stent-grafts on the market, there is no one therapy that works for all young patients.
In the absence of a stent-graft, the decellularized arterial conduits are ineffective. The patient should be kept informed about the risks and potential complications associated with this type of stent. In addition to this, EVAR is not suitable for major side vessels. However, the best-performing EVARs have a cellular composition that matches the patient's natural blood.
Some vascular and arterial prostheses are biocompatible. While they are not considered to be thrombogenic, they may cause adverse reactions. For instance, some of them have been found to increase the risk of cardiovascular disease. This can lead to complications. The stents are not as biocompatible as the blood in the heart. There is no evidence that these EVARs can prevent heart failure.
The most common type of arterial vein and vascular prostheses are recanalized umbilical veins. These are easily harvested conduits and can be used for multiple vascular procedures. In addition to recanalization, they can be utilized as interposition grafts and vein patches. A recanalized umbilical vein has a highly hydrated surface. The material is biocompatible for this type of implantation.
In recent years, research on vascular and arterial grafts has focused on developing biomaterials with characteristics similar to those of humans. PTFE is the most widely used synthetic conduit. Its mechanical properties and neovascularization response make it an excellent choice for small-diameter grafts. This material has minimal inflammatory and thrombogenic properties. It also withstands a range of pressure.
A variety of vascular prostheses are available. The most common synthetic conduit is e-PTFE. Its properties make it a suitable material for graft placement. It has good suture-retention strength and low resistance to infection. It is not an alternative to a synthetic vascular graft. Unlike the artificial graft, e-PTFE is biocompatible.
In a recent study, researchers implanted a membrane-mimetic film onto ePTFE grafts. Their results showed reduced adhesion of platelets and fibrinogen in a baboon femoral arteriovenous shunt model. Furthermore, they demonstrated reduced adhesion of platelets to ePTFE grafts after four and six months.
In the most recent study, a segment of the external iliac artery was resected during CABG. Similarly, the radial artery was used to reconstruct the main trunk of the portal vein during en bloc resection of a hepatoblastoma. Its patency rate was comparable to that of the saphenous vein, but its graft was at higher risk of occlusion. In addition, elevated levels of vasoconstrictors were detected during and after CABG.